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pregnancy. However, these hormones have not been useful in the development of molecular 48 metrics to estimate GA or to phenotype complicated pregnancies prior to overt clinical 49 manifestations of specific pathologic states like preeclampsia (PE) [3, 4] , a pregnancy-related 50 vascular disorder affecting 5-8% of all pregnancies [5, 6] . 51 PE is thought to be a multisystem disorder of pregnancy driven by alterations in placental 52 function and resolved by the delivery of the placenta and fetus [7] . A few pregnancy-associated, 53 placenta-related markers have been observed having different patterns in normal pregnancies and 54 pregnancies with PE. Chorionic somatomammotropin hormone like 1 (CSHL1; also called 55 human placental lactogen) is selectively expressed in placental villi with an important role in 56 regulating placental growth. Leptin (LEP) has been suggested to be involved in placental and 57 fetal growth [8] . The relationship between LEP and PE has been discussed in a few studies [9-58 17] . Circulating levels of activin A, a member of the tumor growth factor protein family, can 59 increase as early as 10-15 weeks of pregnancy in women who subsequently develop PE [18] . 60 Elevated placental levels of angiogenic factors (soluble fms-like tyrosine kinase or sFlt-1) and 61 decreased levels of anti-angiogenic factors (placental growth factor, PlGF) have been implicated 62 in the pathogenesis of PE [19] [20] [21] [22] [23] [24] [25] . As such, the sFlt-1/PlGF ratio has been proposed as an index 63 to diagnose and manage PE [26, 27] . A significant increase in sFlt-1 levels was also observed in 64 sera of pregnant heme oxygenase (HO)-1 heterozygote (Het, HO-1 +/-) mice, where the deficiency 65 in HO-1 results in PE-like symptoms [28] . Recent work by Ho et al showed that PE was 66 associated in mice with a deficiency in elabela (ELA), a placental hormone that enhances human 67 trophoblast invasiveness in vitro [29] . 68 In this study, we chose 6 proteins as candidates of GA estimation because they are 69 associated with the placenta and reflect placental growth. Furthermore, levels of all 6 proteins 70 differ in PE compared to a normal pregnancy. Previous studies found that LEP, CSHL1, and 71 activin A are elevated early in gestation in women who subsequently develop PE [30] [31] [32] . ELA 72 deficiency is associated with PE-like symptoms in mice [29] . The ratio of sFlt-1 and PlGF has 73 been used clinically for diagnosing PE [27] . 74 We hypothesized that serum levels of placenta-related proteins, LEP, CSHL1, ELA, 75 activin A, sFlt-1, and PlGF are longitudinally regulated, and a profile of their circulating levels 76 may collectively reflect a pregnancy-associated protein panel describing the normal progression 77 of a term pregnancy. We further hypothesized that disruptions of this panel in early gestation are 78 associated with placental abnormalities and an increased risk of developing PE. We sought to 79 model the longitudinal changes in protein serum levels to estimate GA. In addition, we explored 80 whether temporal disruptions in these profiles early in gestation are harbingers of placental 81 pathology and subsequent PE. The model was first developed in human sera and then tested in 82 both human and mouse sera. 83
METHODS 84

Study design 85
The study was conducted in three phases: (1) using ELISA methods to characterize the 86 normal pattern of serum placenta-related protein levels; (2) modeling a protein-based GA 87 estimation of normal pregnancies and identifying deviations; and (3) exploration of the protein-88 based GA estimation with a mouse PE model. Sera were collected in the first, second, or third 89 trimesters during pregnancy from women who had normal uncomplicated pregnancies or a 90 diagnosis of PE. Blood was collected at 1 to 3 time-points before week 30 of gestation and prior 91 to a confirmatory diagnosis of PE. The GA of human was determined by ultrasound 92 measurement. In the mouse, sera were collected from pregnant HO-1 Het or wild-type (WT) 93 6 6 dams at 1 to 3 time-points between 7.5 to 18.5 days of gestation. The HO-1 Het mice have 94 elevated diastolic blood pressures and plasma sFlt-1 levels during pregnancies, mimicking the 95 PE syndrome [28] . For the human study, approval was obtained from the Stanford University 96 Institutional Review Board. Blood was collected at Stanford University Medical Center after 97 informed consent was obtained. 98
Animal model study 99
For the mouse study, approval was obtained from the Institutional Animal Care and Use 100 Committee at Stanford University. Mouse line maintenance, genotyping, and bleeding were as 101 previously described [28] . 102
ELISAs 103
Sera from human subjects or mice were collected and measured using commercial kits 104 specific for the human or mouse as follows: LEP (R&D System Inc., MN, USA); CSHL1 105 (Mybiosource, San Diego, CA, USA); ELA (Peninsula Laboratories International, Inc., San 106 Carlos, CA, USA); activin A (R&D System Inc.); sFlt-1 (R&D System Inc.,); and PlGF (R&D 107 System Inc.). 108
Statistical analyses 109
Patient demographic data were analyzed using the "Epidemiological Calculator" (R 110 epicalc package). Hypothesis testing was performed using Mann-Whitney U-tests (two-tailed). 111
Samples collected ≥ 30 weeks of gestation or having any of the placenta-related protein 112 measurements out of limits on the standard curves were excluded from the cohort for modeling. 113 A 10-fold cross-validated elastic net (EN) algorithm [2, 33, 34] was used for multivariate 114 modeling of the ELISA data. The model searches for an optimum β to minimize the least squared 115 loss function with elastic net penalty: 116
where X=(x 1 ,…x 6 ) is a matrix of 6 analytes, with x j =(x 1j ,…x nj ) T , where j=1,…6. y = (y 1 ,…y n ) T is 118 the response (i.e., current GA). n is the number of samples in the training cohort.
is the well-known EN penalty used for controlling 120 the model complexity. The parameters of each penalty were controlled by Table 1 . Maternal blood was collected at one, two, or 146 three time-points during each pregnancy (at early, mid, and late-pregnancies, Fig. 1A ). 10 147 women (4 normal pregnancies, 6 with PE) were excluded from the EN-based modeling because 148 samples either were not collected before 30 weeks of gestation or had at least 1 protein candidate 149 that was out of limits on its standard curve. The latter was done because outliers on the standard 150 curve might cause distortion of continuous regression analysis. There were 30 women (16 151 normal pregnancies, 14 with PE) left after exclusion. Our training cohort included 10 patients 152 who delivered at term (≥ 37 weeks GA). An independent cohort of 6 women who delivered at 153 term and 14 women diagnosed with PE were subsequently enrolled for the validation study on 154 normal pregnancy and the test on PE. 155 157
The approach was also tested with serum samples collected longitudinally from pregnant 158 WT (n = 3 with 11 samples) and HO-1 Het (n = 4 with 15 samples) mice (Additional file 2). 159 Each mouse had 3 or 4 samples collected at E7.5, E10.5, E14.5, and E18.5. 160
A placenta-related, protein-based GA estimation of human pregnancy 161
We hypothesized that circulating placenta-related protein expression throughout 162 pregnancy reflects the normal temporal progression of human gestation, and effectively serves to 163 estimate GA. Using an EN algorithm, we developed a 6-protein model using a training cohort of 164 10 pregnant women that was strongly associated with GA at the time of sampling (R 2 = 0.76, P = 165 2x10 -7 , Fig Additional file 3 and 4. Together, the analyses confirmed that there is a highly-regulated 170 temporal pattern of protein levels in sera over the course of pregnancy ( Fig. 1B) . 171
The placenta-related, protein-based GA estimation malfunctions in PE 172
Based on the above findings, we hypothesized that our EN model can identify abnormal 173 phenotypes, such as in PE that may have an attendant disrupted placenta-related protein pattern. 174
In contrast to the normal cohort (training R 2 = 0.76 and testing R 2 = 0.61, Fig. 1B ), the EN model 175 did not predict GA at time of sampling and yielded random data predictions in the PE cohort 176 The pathogenesis of PE is complex and progresses from an asymptomatic stage, 179 characterized by placental abnormalities during the first trimester to a symptomatic stage with 180 proteinuria and hypertension in late gestation [35] . Our analyses revealed unique longitudinal 181 patterns of serum protein levels of specific biomarkers ( 
Comparative analysis of serological GA estimation between the human and a mouse model 223
We hypothesized that similar temporal placenta-related protein expression patterns 224 should be conserved in mouse pregnancies, therefore, we explored our EN- PE is based on the presence of maternal hypertension and proteinuria [38] . Previous 252 transcriptomic [39] [40] [41] [42] [43] [44] [45] and proteomic [2, [46] [47] [48] [49] [50] Our findings of serum protein levels during a normal pregnancy are consistent with those 261 from previous studies. They are in line with the ranges reported in healthy pregnancies and have 262 similar patterns during the pregnancy as previous results [51] [52] [53] [54] [55] [56] [57] [58] [59] . We found that LEP increased 263 continuously during the first and second trimesters. Activin A remained stable between 10-20 264 weeks of gestation and increased late in the second trimester. sFlt-1 levels were also unchanged 265 before 30 weeks, while PlGF progressively rose over pregnancy. We further integrated the 266 quantitative trending information of each individual protein into a continuous regression model 267 that expressed GA as a linear combination of the levels of proteins. 268 Current challenges in the management of PE include lack of early assessment and 269 incomplete understanding of its pathogenesis and pathophysiology at early GAs. sFlt-1 and PlGF 270 are well-established PE biomarkers [60] with clinical prognostic utilities in PE management. The 271 ratio of sFlt-1 and PlGF has been shown to effectively differentiate PE from normal term 272 pregnancies after 25 weeks of gestation [27] . Our findings that LEP, CSHL1, activin a, and ELA 273 have unique serum protein signatures, starting from early to mid-gestation, are novel and that 274 disruptions in the normal temporal placenta-related protein pattern appear at earlier GA than the 275 conventional PE biomarkers sFlt-1 or PlGF. The presence of high levels of LEP in early 276 gestation may signify the impending development of PE and thus serve as an early biomarker of 277 PE. Our analyses show that LEP can differentiate PE from normal term pregnancies at <25 278 weeks (P = 3x10 -6 at 15-25 weeks), earlier than sFlt-1, which is consistent with the previous 279 findings of other studies [61, 62] . Given that LEP is a master regulator of energy expenditure, the 280 observations suggest that placental insufficiency through energy imbalance is a precursor to PE 281 that is manifested as hypertension in mid-late gestation. 282
Our characterization of temporal patterns of protein levels in mice provided additional 283 support for our hypothesis. Applying our multivariate EN modeling on mouse sera we also found 284 an association of protein levels and GA during normal mouse pregnancies, and this relationship 285 was disrupted in pregnant HO-1 Het mice. Among the 5 proteins studied, LEP had the largest 286 fold change in PE-like (HO-1 Het) pregnancies. The main action of leptin is in the maternal 287 interface during the first stage of pregnancy regulating angiogenesis, growth and 288 immunomodulation on the placenta [63] [64] [65] [66] [67] [68] [69] . Although dysregulation of leptin levels has been 289 found correlated with the pathogenesis of various pregnancy disorders [70] , including PE, the 290 exact mechanism of action and upstream regulators remain unknown. Our characterization of the 291 pregnant HO-1 Het mouse PE model, for the first time, provides direct evidence of the causative 292 action of HO-1 deficiency in leptin upregulation in a PE-like murine model. This result, together 293 with the significant differentiating power of LEP at < 25 weeks GA in human pregnancies may 294 indicate a mechanistic role of LEP and HO-1 in the pathogenesis of PE, and deregulation of LEP 295 as an indicator of impending PE. 296
We note that placenta-related proteins have distinct temporal patterns and share common 297 characteristics between human and rodent pregnancies. sFlt-1 is upregulated in late gestation of 298 pregnant women with PE or pregnant HO-1 Het mice. Elevated sFlt-1 levels late in gestation in 299 mice are consistent with the findings of a previous study [28] . PlGF is upregulated after 14.5 300 days GA in mice while significantly down-regulated after 27 weeks GA in humans with 301 complicated pregnancies. LEP had a significant role in identifying PE or PE-like pregnancies of 302 both human and mice. The maximum differentiating power of LEP is achieved at late gestation 303 (18.5 days) in mice but in early gestation (< 25 weeks) in humans. The differences in placenta-304 related protein patterns between humans and mice may be explained by the different placental 305 structures (e.g. a choriovitelline placenta is initially present in mice but absent in human; 306 trophoblast cell invasion is restricted in mice but deep in human) and different placental 307 endocrine functions [71] [72] [73] . Despite these differences, the similar physiological features shared 308 in human and mouse placentas, and the associations between proteins and GA in both human and 309 mice observed in our study, show that PE-related patterns found in human are preserved in mice. 310
It also demonstrates that studies on rodent models can be used to study the biology of human 311 pregnancy disorders. 312
This study has several limitations. First, the sample sizes for our human cohorts were 313 small, and our population lacked racial heterogeneity. Second, the time intervals of blood 314 collections between two serial samples varied (3-31 weeks for normal, and 3-25 weeks for PE). 315
Most samples were collected in the first or second trimester. Only 12 normal and 9 PE patients 316 had samples collected in the third trimester. Third, serum concentrations of LEP can be 317 influenced by maternal status [74, 75] . We addressed this through the normalization to maternal 318 BMI (Additional file 6) and found the temporal pattern in LEP persisted. Fourth, variations in 319 circulating protein levels could be due to the contributions from other tissues besides the 320 placenta. Meta-analysis of PE and GA-matched uncomplicated pregnancy-associated placental 321 gene expression patterns, including the targeted analytes of this study, has revealed similar 322 expression trending along the gestations and differentiation between PE and normal controls 323 [76] . Fifth, ELA was not included in the rodent analyses due to the lack of the robustness of the 324 mouse ELISA assay. Sixth, although our protein candidates formed a panel of potential clinical 325 utility to assess impending PE, the model robustness can be greatly improved by refinements 326 using a sufficiently powered high time resolution cohort of sufficient powered sample size. 
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